RNA editing to predict antidepressant response in unipolar and bipolar depression

RNA Editing as a Biomarker of Antidepressant Response in Unipolar and Bipolar Depression (EDIT-ANDRE)

This project tests whether changes in RNA editing can predict how adults with unipolar or bipolar depression respond to antidepressant treatment.

Quick facts

• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Mayo Clinic (Academic / other)
• Drugs / interventions: chemotherapy
• Locations: 1 site (Rochester, Minnesota)
• Trial ID: NCT07266545 on ClinicalTrials.gov

What this trial studies

Adults aged 18–65 with a current major depressive episode (MDD, BD-I, or BD-II) and QIDS-C16 >10 will be enrolled at Mayo Clinic in Rochester. Participants receive standard antidepressant treatments (vortioxetine or bupropion extended release), with cariprazine allowed as an augmentation option, and BD-I patients must remain on a mood stabilizer. Researchers will collect samples to measure RNA editing changes over the treatment course while tracking depressive symptoms and clinical response. The study aims to link molecular RNA editing patterns with treatment outcomes to see if editing can serve as a biomarker for antidepressant response.

Who should consider this trial

Good fit: Adults 18–65 with a current major depressive episode due to MDD, BD-I, or BD-II, a QIDS-C16 score >10, ability to travel to Rochester, and for BD-I, stable use of a mood stabilizer, are ideal candidates.

Not a fit: People outside the 18–65 age range, those without a current major depressive episode or with milder symptoms (QIDS-C16 ≤10), pregnant individuals, or those unable to travel to Mayo Clinic Rochester are unlikely to benefit.

Why it matters

Potential benefit: If successful, this could enable more personalized antidepressant choices by identifying patients likely to respond to specific medications.

How similar studies have performed: RNA editing as a biomarker is a relatively new approach with limited preliminary evidence in mood disorders, but it has not yet been validated as a reliable clinical predictor.

Eligibility criteria

Inclusion Criteria:

* Adult females and males, aged 18-65 years
* Must have the capacity to understand study procedures, to comply with them for the entire length of the study, and to provide informed consent.
* Current major depressive episodes associated with MDD, BD-I, or BD-II, confirmed using the SCID-IV-CV.
* Symptom severity score on the Quick Inventory for Depressive Symptomatology - Clinician (QIDS-C16) \> 10.
* Ability to travel for assessment visits.
* Negative urine pregnancy test for people of childbearing potential
* People of childbearing potential must be using an acceptable method of birth control during the study, such as hormonal contraception, intrauterine device, bilateral tubal ligation, partner's documented vasectomy, or complete abstinence from intercourse with childbearing potential, with barrier methods permitted only when used in combination with one of these primary methods.
* BD-I patients must be on a mood stabilizer (i.e., lithium, valproate, or a mood-stabilizing atypical antipsychotic at least for one month) at the time of enrollment Exclusion Criteria

All candidates meeting any of the following criteria at baseline will be excluded from study participation:

* Individuals who cannot understand English will not be enrolled because informed consent, study procedures, and interviews require comprehension of English.
* Inability to provide written, voluntary informed consent
* Failure to score at least 75% on a 4-item comprehension assessment related to study goals, risks, and benefits
* For BD-I: not having used at least one mood stabilizer (e.g., lithium, valproate, or mood-stabilizing antipsychotics) at a stable dose and within a therapeutically effective antimanic range for a minimum of one month.
* History of treatment-refractory depression, defined as non-response to two or more antidepressant or mood-stabilizing regimens despite adequate dose, duration, and adherence during the current episode.
* Participants with active suicidal ideation, defined as a MADRS item #10 score greater than 4 or a "yes" response to item #4 (ideation with intent) or item #5 (ideation with plan) on the C-SSRS, will be excluded
* A medically serious suicide attempt within the past 6 months, defined as requiring emergency department evaluation, a medical procedure, or admission to a hospital (e.g., internal medicine, cardiology, or ICU)
* Current use of monoamine oxidase inhibitors or use within 14 days following discontinuation of a monoamine oxidase inhibitor
* Presence of mixed symptoms of depression, defined as a YMRS score ≥12
* Current use of any of the study medications (e.g., vortioxetine, bupropion, or cariprazine) at the time of enrollment (previous use of these medications is acceptable)
* Prior hypersensitivity reaction or documented non-response to any of the study medications
* A history of seizure disorder; complicated febrile convulsions (e.g., prolonged, focal, or recurrent); current or past diagnosis of bulimia nervosa or anorexia nervosa; or any condition known to lower seizure threshold, including abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.
* Known CYP2D6 or CYP2B6 poor metabolizer status, or a history of intolerance to medications primarily metabolized by these enzymes (e.g., vortioxetine, bupropion, SSRIs, efavirenz), due to increased risk of side effects.
* Recent use (within the past 4 weeks) of long half-life psychotropic medications with active metabolites that may interfere with study outcomes, including fluoxetine and long-acting injectable forms of aripiprazole and paliperidone.
* Active psychosis, defined as a YMRS item #8 score \>4 or diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or schizophreniform disorder as determined by structured clinical interview
* Current drug or alcohol use disorder (excluding nicotine); full remission for at least 3 months is required for eligibility
* Positive toxicology screen for illicit substances (e.g., cocaine, methamphetamine, illegal opiates). Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included in the study only if they take the CUDIT-R and score a 12 or less.
* Individuals who are pregnant, lactating, trying to conceive, or not using adequate contraception (e.g., hormonal contraception, intrauterine device, tubal ligation, or condoms)
* Any active or unstable medical condition judged by the principal investigator to confer excessive risk
* Clinically significant laboratory abnormality, uncontrolled hypertension (blood pressure \>160/100 mmHg), or tachycardia (heart rate \>110 bpm)
* Significant renal, hepatic, or cardiac disease; malignancy; autoimmune disease; or chronic kidney disease \> stage IIIa (estimated GFR \< 60 mL/min/1.73 m²)
* History of traumatic brain injury or gastric bypass
* Clinical diagnosis of delirium, encephalopathy, intellectual disability or cognitive disorder (mild or major neurocognitive disorder)
* Currently receiving electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) as acute or maintenance treatment
* Current use of systemic steroids, chemotherapy, radiotherapy, or undergoing involuntary psychiatric hospitalization
* Daily use of lorazepam (Ativan) \>4 mg/day, or equivalent doses of other benzodiazepines (e.g., clonazepam \>1 mg, alprazolam \>2 mg, diazepam \>20 mg)
* No access to smartphones, internet

All candidates meeting any of the following criteria at baseline will be excluded from the Phase 2 (cariprazine add-on) of the study:

* Meeting symptomatic remission criteria based on MADRS (≤ 10).
* Current use of a strong or moderate CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, fluconazole, or verapamil) or a strong CYP3A4 inducer (e.g., carbamazepine, rifampin, phenytoin, or St. John's Wort), due to potential pharmacokinetic interactions with cariprazine.
* Diagnosis of BD-I with concurrent use of an antipsychotic agent as a mood stabilizer.

Where this trial is running

Rochester, Minnesota

• Mayo Clinic in Rochester — Rochester, Minnesota, United States (Recruiting)

Study contacts

• Principal investigator: Aysegul Ozerdem, MD, PhD — Mayo Clinic
• Study coordinator: Scott E. Feeder

Conditions Unipolar Depression; Bipolar Depression